The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The SERPENTINE trial: A phase II clinical study decoding immune responses by scRNA-seq and TCR-seq analysis in patients with MSS metastatic colorectal cancer (mCRC) with and without liver metastases treated with durvalumab and tremelimumab.
 
Iosune Baraibar
Honoraria - Amgen; AstraZeneca
Travel, Accommodations, Expenses - Amgen; Merck; SERVIER
 
Sam Morabito
No Relationships to Disclose
 
Juan Nieto
No Relationships to Disclose
 
Gerard Deuner
No Relationships to Disclose
 
Juan Luis Melero
No Relationships to Disclose
 
Francesc Salva
No Relationships to Disclose
 
Marta Grzelak
No Relationships to Disclose
 
Javier Ros Montañá
Honoraria - Amgen
Speakers' Bureau - Amgen; BMS GmbH & Co. KG; Merck KGaA; Pfizer; Sanofi; Takeda
Travel, Accommodations, Expenses - Amgen; Amgen; Merck; Pierre Fabre; SERVIER
 
Ginevra Caratu
No Relationships to Disclose
 
Raquel Perez-Lopez
No Relationships to Disclose
 
Paula Nieto
No Relationships to Disclose
 
Asaf Rotem
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Patricia Casbas-Hernandez
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Nadia Martinez-Martin
Employment - Astra ZenecaAstra Zeneca
Stock and Other Ownership Interests - AstraZeneca
 
Alena Gros
No Relationships to Disclose
 
Josep Tabernero
Stock and Other Ownership Interests - 1TRIALSP; Alentis Therapeutics; Oniria Therapeutics; Pangaea Oncology
Consulting or Advisory Role - Accent Therapeutics; Alentis Therapeutics; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Carina Biotech; Cartography Biosciences; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; Johnson & Johnson/Janssen; Larkspur Biosciences Inc; Lilly; Marengo Therapeutics; Menarini; Merus; MSD; Novartis; One-carbon Therapeutics AB; Ono Pharmaceutical; Peptomyc; Pfizer; Pierre Fabre; Quantro Therapeutics; Scandion Oncology; Scorpion Therapeutics; Servier; Sotio; Syntelios AG; Taiho Pharmaceutical; Takeda Pharmaceuticals International AG; Theriva Biologics; Tolremo
 
Elena Elez
Honoraria - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson&Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Rottapharm Biotech; Sanofi; Seagan; SERVIER; Takeda
Consulting or Advisory Role - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson&Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics Inc.; RIN Institute Inc.; Roche; Rottapharm Biotech; Sanofi; Seagan (Inst); SERVIER; Takeda
Speakers' Bureau - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson & Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute; Roche; Rottapharm Biotech; Sanofi; Seagan (Inst); SERVIER; Takeda
Research Funding - 1Globe Health Institute (Inst); Agenus (Inst); Amgen (Inst); Artios (Inst); AstraZeneca (Inst); Biontech Rna Pharmaceuticals Gmbh (Inst); Biontech Small Molecules Gmbh (Inst); Bristol-Myers Squibb International Corporation (Bms) (Inst); Cancer Research UK (Inst); Exelixis (Inst); Fédération Francophone De Cancérologie Digestive (Inst); Fundación CRIS Contra el Cáncer (Inst); GlaxoSmithKline (Inst); Grupo de Tratamiento de los Tumores Digestivos (TTD) (Inst); Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD) (Inst); INCLIVA Institut d'Investigació Sanitària (Inst); InhibRx (Inst); Instituto de Salud Carlos III (ISCIII) (Inst); Istituto Fondazione AIRC di Oncologia Molecolare (IFOM) (Inst); Janssen Research & Development (Inst); Janssen-Cilag SA (Inst); Merck (Inst); Merck, Sharp & Dohme de España SA (Inst); Msd Regional Business Support Center Gmbh (Inst); Nouscom (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson&Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Rottapharm Biotech; Sanofi; Seagan; SERVIER; Takeda